Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Trial pipeline

Track psilocybin trial phases, recruitment, sponsors and registry completion dates with country filters, source links, comparison and free data exports.

Free access · No subscription for research tools or data exports

Filter the development pipeline

Reset

14 trials match this view; 15 reported facilities; 15 have usable coordinates. Latest indexed registry check Nov 19, 2026 02:23 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 628 across 14 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

20041
20071
20121
20211
20231
20243
20251
20264
20271

Current indexed registry status

Recruiting5
Completed3
Not yet recruiting2
Withdrawn2
Active, not recruiting1
Unknown status1

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Milestones to investigate

The table is ordered by reported primary completion date. Check whether the registry calls enrollment estimated or actual, when the record was last updated, and whether results have been published. Completion dates are not readout dates; no model-generated success probabilities are assigned.

For late-stage studies, choose PHASE3 above. For studies still underway, choose an exact recruitment status. Use sponsor and country filters to inspect a programme, then save records to compare their designs.

Matching trial records

14 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744

Anxiety
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

PHASE1, PHASE2

Completed

Registry updated 2025-03-13

12

ACTUAL

2004-04
2008-12
2008-12
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.

NCT00979693

Anxiety · Stage IV Melanoma
Multidisciplinary Association for Psychedelic Studies

PHASE2

Withdrawn

Registry updated 2023-12-26

0

ACTUAL

2012-01
2013-04
2013-06
Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595

Depressive Symptoms · Anxiety · Cancer
Johns Hopkins University

PHASE2

Completed

Registry updated 2018-07-19

56

ACTUAL

2007-04
2014-12
2016-12
Evidence-guide report · Griffiths et al. · 2016
Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study

NCT05252598

Mood Disturbance · Mood Change · Sleep Disturbance · Drug Effect · Psychedelic Experiences · Health, Subjective · Psilocin Toxicity · Psilocybin Toxicity · Psilocybin Causing Adverse Effects in Therapeutic Use · Anxiety
Optimi Health Corporation

EARLY_PHASE1

Withdrawn

Registry updated 2023-03-20

0

ACTUAL

2023-01
2023-08
2023-12
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

NCT04932434

Parkinson Disease · Depression · Anxiety
Joshua Woolley, MD, PhD

PHASE2

Completed

Registry updated 2026-09-03

12

ACTUAL

2021-08-15
2024-12-31
2024-12-31
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT06444243

Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
University of Sydney

PHASE2

Unknown status

Registry updated 2024-06-10

90

ESTIMATED

2024-09
2025-07
2025-12
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

NCT07336238

Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
University of Washington

PHASE2

Active, not recruiting

Registry updated 2026-10-29

16

ACTUAL

2026-05-19
2026-12-01
2027-05-01
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

NCT06801041

Depression · Anxiety · Cancer
M.D. Anderson Cancer Center

PHASE2

Recruiting

Registry updated 2026-11-03

20

ESTIMATED

2025-05-23
2027-03-31
2029-03-31
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

NCT06442423

Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms · PTSD · Substance Use · Substance Use Disorder (SUD) · OCD
Yale University

PHASE1

Recruiting

Registry updated 2026-11-16

50

ESTIMATED

2024-10-17
2027-12
2027-12
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression

NCT07565909

Depression · Anxiety
University of Washington

PHASE2

Not yet recruiting

Registry updated 2026-05-04

72

ESTIMATED

2026-06
2027-12
2028-07
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

NCT06820723

Depression · Anxiety · Major Depressive Disorder
Ohio State University

PHASE2

Recruiting

Registry updated 2026-10-20

40

ESTIMATED

2026-11-01
2028-11
2028-11
Registry-linked result · PMID 27210031
Registry-linked result · PMID 33146667
Registry-linked result · PMID 36322843
Registry-linked result · PMID 31060042
Registry-linked result · PMID 31636488
Registry-linked result · PMID 37651119
Registry-linked result · PMID 27909164
Registry-linked result · PMID 20717121
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy

NCT06899165

Psychological Stress · Depression · Anxiety
Rachel Yehuda

PHASE2

Recruiting

Registry updated 2026-08-13

100

ESTIMATED

2026-08-28
2029-05-31
2030-01-02
Psilocybin FCR Early-Stage Breast Cancer

NCT07909408

Early-stage Breast Cancer · Fear of Cancer Recurrence · Anxiety · Depression
NYU Langone Health

PHASE2

Not yet recruiting

Registry updated 2026-11-02

100

ESTIMATED

2027-01-02
2031-01-02
2031-08-31

Reported research facilities

Spital Uster AG, Division of Internal MedicineUster, Switzerland · Coordinates available
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland · Coordinates available
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland · Coordinates available
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland · Coordinates available
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview CampusBaltimore, Maryland, United States · Coordinates available
Connecticut Mental Health Center - Yale School of MedicineNew Haven, Connecticut, United States · Coordinates available
Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States · Coordinates available
Harbor-UCLA Medical CenterTorrance, California, United States · Coordinates available
Mount Sinai Comprehensive Cancer CenterMiami Beach, Florida, United States · Coordinates available
NYU Langone HeathNew York, New York, United States · Coordinates available
The Ohio State University Department of PsychiatryColumbus, Ohio, United States · Coordinates available
The Parsons Research Center for Psychedelic HealingNew York, New York, United States · Coordinates available
The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States · Coordinates available
University of California, San FranciscoSan Francisco, California, United States · Coordinates available
University of Colorado Anschutz Medical Campus (CUAMC)Aurora, Colorado, United States · Coordinates available

This directory includes reported facilities with and without coordinates. For a country-filtered view, locations are labeled as selected-country sites or international sites of matching trials. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.